WeightWatchers is struggling. Launched in the early 1960s, the brand grew by helping members shed pounds through behavioural change programmes. Then, GLP-1 anti-obesity drugs hit the market, long-time spokesperson and board member Oprah Winfrey announced her departure, and the company’s credit rating was downgraded. FT reporter Anna Mutoh examines whether WeightWatchers’ latest strategy can produce the turnaround investors are hoping for.
Clip from Lionsgate Television
- - - - - - - - - - - - - - - - - - - - - - - - - -
For further reading:
WeightWatchers faces an era when weight loss comes in a syringe
Behold the Ozempic effect on business
The race to develop the next generation of weight-loss drugs
- - - - - - - - - - - - - - - - - - - - - - - - - -
On X, follow Anna Mutoh (@anna_mutoh) and Michela Tindera (@mtindera07), or follow Michela on LinkedIn for updates about the show and more.
Read a transcript of this episode on FT.com
Hosted on Acast. See acast.com/privacy for more information.
Why Elon Musk is breaking up with Delaware
Baidu’s ‘do-or-die’ bet on AI
Is this nuclear power’s moment?
Introducing: Swamp Notes from The FT News Briefing
BlackRock goes all in on infrastructure
An IPO drought pushes investors to a murky marketplace
Introducing Untold: The Retreat
Ozempic’s unconventional origins
Listener mailbag with Martin Wolf & more
TED Talks Daily: The next global superpower isn’t who you think
Author Amy Edmondson on ‘intelligent failure’
The ‘Ponzi scheme’ behind Lebanon’s economic collapse
Could COP28 catapult the carbon credit market?
Inside a hedge fund disaster
Best Of: Why companies don't want to list in the UK anymore
Introducing: Life and Art, from FT Weekend
Citigroup reboots
Coming soon: Superintelligent AI
Will the union ‘renaissance’ last?
Big Oil’s big bet
Create your
podcast in
minutes
It is Free
The emPOWERed Half Hour
FT News Briefing
Money Clinic with Claer Barrett
FT World Weekly
FT News in Focus
FT Banking Weekly